Document text
Principal Investigator: Peter B. Gilbert
Organization: FRED HUTCHINSON CANCER CENTER
Fiscal Year: 2022
Award: $453,649
Funding agency: National Institute of Allergy and Infectious Diseases
Project Abstract
This proposal outlines the scientific agenda for the COVID-19 Prevention Network (CoVPN) Vaccines
Leadership Operations Center (LOC) for implementation of the COVID-19 vaccine trial entitled “A randomized
controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in
university students immunized with Moderna COVID-19 Vaccine.”
With the global COVID-19 pandemic, we recognize a significant need for SARS-CoV-2 vaccines that reduce
infection in exposed individuals, reduce the amount of viral shedding in infected individuals and reduce
transmission from infected individuals to close contacts. Addressing the COVID-19 pandemic, the National
Institutes of Health (NIH) led rapid constitution of the CoVPN, partnering 5 NIH supported clinical trial networks,
to create an enhanced network of physician-scientists at 145 United States (US) and 71 international clinical trial
sites in 17 countries dedicated to developing globally effective vaccines for SARS-CoV-2. Due to its extensive
experience implementing global HIV vaccine trials over the last 20 years, the HIV Vaccine Trials Network (HVTN)
LOC was selected as the LOC for CoVPN vaccine trials.
This study will monitor the efficacy of the Federal Drug Administration (FDA) Emergency Use Authorized (EUA)
Moderna COVID-19 Vaccine to prevent infection in an immediate versus delayed vaccination college student
cohort. Participants will be recruited from over 20 universities across the United States and will include three
cohorts: 12,000 healthy volunteers aged 18 through 26 years to receive immediate (month 0) or delayed (month
4) vaccination (Main Cohort), up to 24,000 volunteers subject to university SARS-CoV-2 testing who are in close
physical proximity with main cohort participants (Prospective Close Contact (PCC) Cohort), and approximately
3 contacts per incidence case for a total of up to 1,500 individuals who have been in close contact with a SARS-
CoV-2 positive case from the Main Cohort (Case-Ascertained Close Contact (CACC) Cohort).
Participants in the main study will be unblinded to randomization and will be administered vaccine at day 1 (D1)
and D29 for the immediate vaccination arm, and at D113 and D141 for the delayed vaccination arm. They will
self-collect nasal swabs daily in order to capture all incident SARS-CoVE-2 infection events over 4 months of
follow-up and to capture the full course of viral shedding – from onset of infection to viral clearance – among
those with both asymptomatic and symptomatic infection. To minimize participant burden and maximize study
efficiency many study procedures will occur remotely. SARS-CoV-2 infected participants will complete daily e-
diaries to capture symptoms. All trial endpoint assays will be done using qualified and validated assays for
diagnosis and immune monitoring and the primary analyses will be conducted among baseline seronegative
participants (targeting an entry seropositive rate of < 10%).
Specific aims of this study are to assess the clinical efficacy of the Moderna COVID-19 Vaccine to prevent SARS-
CoV-2 infection in naïve adults; to evaluate the vaccine effect on peak nasal viral load as a measure of infection
and proxy of infectiousness; to evaluate the impact of the vaccine on secondary transmission of SARS-CoV-2
infection; to evaluate vaccine efficacy against COVID-19 disease; and to evaluate the immunogenicity of the
vaccine. This trial will add a great deal to our understanding on how effective these vaccines are in reducing
and modifying infection as well as preventing transmission to persons living near vaccinated individuals. It will
also improve our understanding of the viral dynamics in SARS-CoV-2 mRNA vaccinated individuals. Lastly, the
results of this trial will be used to modify future COVID-19 vaccine trials targeting both personal protection and
prevention of transmission.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><21+ years old><Abdominal Typhus><Active Follow-up><Address><Adult><Adult Human><Assay><Bioassay><Biologic Assays><Biological Assay><Biometrics><Biometry><Biostatistics><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 Prevention Network><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 positive><COVID-19 positivity><COVID-19 public health crisis><COVID-19 severity><COVID-19 testing><COVID-19 transmission><COVID-19 vaccine><COVID-19 virus><COVID-19 virus transmission><COVID19><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 outbreak><COVID19 pandemic><COVID19 positive><COVID19 positivity><COVID19 public health crisis><COVID19 severity><COVID19 testing><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cellular Assay><Cellular Immune Function><Clinical><Clinical Trials><Clinical Trials Network><CoV-2><CoV2><CoVPN><Cohort Studies><Communicable Diseases><Concurrent Studies><Constitution><Coronaviridae><Coronavirus><Country><Development><Diagnosis><Disease><Disorder><Drugs><Emergencies><Emergency Situation><End Point Assay><Endpoint Assays><Enteric Fever><Event><Eye><Eyeball><Future><Goals><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS Vaccines><HVTN><Health><Immune><Immune Monitoring><Immune response><Immunes><Immunity><Immunize><Immunologic Monitoring><Immunological Monitoring><Immunological response><Immunology><Immunomonitoring><Incidence><Individual><Infection><Infection Control><Infection prevention><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><International><Knowledge><Laboratories><Lead><Leadership><Malaria><Measures><Mediating><Medication><Messenger RNA><Moderna COVID-19 vaccine><Moderna coronavirus disease 2019 vaccine><Monitor><Morbidity><Morbidity - disease rate><NIH><Nasal><Nasal Passages Nose><National Institutes of Health><Nose><Paludism><Participant><Pb element><Persons><Pharmaceutic Preparations><Pharmaceutical Preparations><Phase><Physicians><Plasmodium Infections><Population><Preparation><Prevent infection><Prevention><Procedures><Protocol><Protocols documentation><Proxy><Quality Control><Randomized><Randomized Clinical Trials><Research Methodology><Research Methods><Respiratory System, Nose, Nasal Passages><Risk><SARS><SARS corona virus 2><SARS coronavirus disease><SARS-CO-V2><SARS-COVID-2><SARS-CoV disease><SARS-CoV-2><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 positive><SARS-CoV-2 positivity><SARS-CoV-2 severity><SARS-CoV-2 testing><SARS-CoV-2 transmission><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 outbreak><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Scientist><Serology test><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome coronavirus disease><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 positive><Severe acute respiratory syndrome coronavirus 2 positivity><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Site><Symptoms><System><Transmission><Typhoid><Typhoid Fever><United States><United States National Institutes of Health><Universities><Vaccination><Vaccinee><Vaccines><Validation><Viral><Viral Burden><Viral Load><Viral Load result><Viral Shedding><Virus Shedding><Wuhan coronavirus><active followup><adulthood><aged><arm><cell assay><clinical efficacy><clinical trial analysis><cohort><college student><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 positive><coronavirus disease 2019 positivity><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 severity><coronavirus disease 2019 testing><coronavirus disease 2019 transmission><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease 2019 virus transmission><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><design><designing><developmental><diaries><drug/agent><efficacy analysis><efficacy assessment><efficacy evaluation><efficacy examination><efficacy study><efficacy trial><evaluate efficacy><evaluate vaccines><examine efficacy><experience><follow up><follow-up><followed up><followup><hCoV19><healthy volunteer><heavy metal Pb><heavy metal lead><host response><human immunodeficiency virus vaccine><immune function><immune system response><immunoresponse><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><infection rate><mRNA><mRNA-1273><mRNA1273><mortality><nCoV2><nasal swab><operation><prevent><preventing><programs><prospective><quality assurance><randomisation><randomization><randomized control study><randomized controlled study><randomly assigned><rate of infection><recruit><response><serology assay><seropositive><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 severity><severe acute respiratory syndrome coronavirus 2 testing><severe acute respiratory syndrome coronavirus 2 transmission><transmission process><transmitted COVID-19><transmitted SARS-CoV-2><transmitted coronavirus disease 2019><transmitted severe acute respiratory syndrome coronavirus 2><university student><vaccinated individual><vaccinated participant><vaccinated patient><vaccinated person><vaccinated subject><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine efficacy><vaccine evaluation><vaccine for novel coronavirus><vaccine immune response><vaccine immunogenicity><vaccine screening><vaccine study><vaccine testing><vaccine trial><volunteer>